Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant therapy for melanoma.

V K Sondak1

  • 1Division of Surgical Oncology, University of Michigan Medical School, Ann Arbor, USA.

Cancer Journal (Sudbury, Mass.)
|August 16, 2001
PubMed
Summary
This summary is machine-generated.

Adjuvant therapy, including interferon-alpha (IFN-alpha) and vaccines, improves survival for melanoma patients with deep tumors or lymph node involvement. Radiation therapy may also reduce recurrence in node-positive cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Correction to: Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?

Annals of surgical oncology·2020
Same author

Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?

Annals of surgical oncology·2020
Same author

Genetic variations in the epidermodysplasia verruciformis (EVER/TMC) genes, cutaneous human papillomavirus infection and squamous cell carcinoma of the skin.

The British journal of dermatology·2015
Same author

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.

Oncogene·2015
Same journal

Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Management of Classic Hodgkin Lymphoma in Special Clinical Situations.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Older Patients With Hodgkin Lymphoma: A Contemporary Review.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy.

Cancer journal (Sudbury, Mass.)·2026
See all related articles

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • Melanoma patients with deep primaries or lymph node metastasis often require adjuvant therapy post-surgery.
  • Current adjuvant strategies aim to improve disease-free and overall survival rates.

Purpose of the Study:

  • To review various adjuvant treatment strategies for high-risk melanoma.
  • To discuss the efficacy and application of interferon-alpha (IFN-alpha) and vaccine therapies.
  • To explore the role of radiation therapy in managing regional recurrence.

Main Methods:

  • Review of randomized trials and preliminary studies on adjuvant therapies for melanoma.
  • Analysis of data on interferon-alpha (IFN-alpha) efficacy, dosage, and scheduling.
  • Evaluation of studies involving melanoma vaccines and adjuvant radiation therapy.

Related Experiment Videos

Main Results:

  • Randomized trials show significant improvements in disease-free and overall survival with IFN-alpha adjuvant therapy, leading to FDA approval.
  • A study comparing high-dose IFN-alpha to GMK vaccine demonstrated superior outcomes with IFN-alpha.
  • Preliminary data suggest adjuvant vaccines and post-operative radiation may reduce recurrence rates in specific patient groups.

Conclusions:

  • Interferon-alpha (IFN-alpha) is an established adjuvant therapy for high-risk melanoma.
  • Melanoma vaccines and selective radiation therapy show promise as adjuvant treatments.
  • Further research is warranted to optimize adjuvant strategies for melanoma management.